TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in two upcoming investor conferences.
The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 5:35 p.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:00 a.m. ET. Both presentations will be available via webcast on the company's investor relations website for 90 days following the events.
TScan Therapeutics (Nasdaq: TCRX), una società biotech in fase clinica che sviluppa terapie con cellule T ingegnerizzate tramite recettori TCR per il trattamento del cancro, ha annunciato la sua partecipazione a due prossimi incontri con investitori.
La società terrà una presentazione al Morgan Stanley 23rd Annual Global Healthcare Conference il 9 settembre 2025 alle 17:35 ET e al H.C. Wainwright 27th Annual Global Investment Conference il 10 settembre 2025 alle 09:00 ET. Entrambe le presentazioni saranno disponibili in webcast sul sito degli investor relations della società per 90 giorni dopo gli eventi.
TScan Therapeutics (Nasdaq: TCRX), una biotecnológica en fase clínica que desarrolla terapias con células T modificadas con receptores TCR para el tratamiento del cáncer, ha anunciado su participación en dos próximas conferencias para inversores.
La compañía realizará una presentación en la Morgan Stanley 23rd Annual Global Healthcare Conference el 9 de septiembre de 2025 a las 5:35 p.m. ET y en la H.C. Wainwright 27th Annual Global Investment Conference el 10 de septiembre de 2025 a las 9:00 a.m. ET. Ambas presentaciones estarán disponibles en webcast en la web de relaciones con inversores de la compañía durante 90 días tras los eventos.
TScan Therapeutics (Nasdaq: TCRX)는 암 치료를 위한 TCR 엔지니어드 T 세포 요법을 개발 중인 임상 단계의 바이오기업으로, 다가오는 두 차례의 투자자 컨퍼런스에 참여한다고 발표했습니다.
회사는 Morgan Stanley 23rd Annual Global Healthcare Conference에서 2025년 9월 9일 오후 5시 35분(ET)에 발표를 하고, H.C. Wainwright 27th Annual Global Investment Conference에서는 2025년 9월 10일 오전 9시(ET)에 발표를 진행할 예정입니다. 두 발표 모두 행사 후 90일간 회사 IR 사이트를 통해 웹캐스트로 시청할 수 있습니다.
TScan Therapeutics (Nasdaq: TCRX), une société biotech en phase clinique développant des thérapies par cellules T ingénierisées avec récepteurs TCR pour le traitement du cancer, a annoncé sa participation à deux prochaines conférences investisseurs.
La société présentera lors de la Morgan Stanley 23rd Annual Global Healthcare Conference le 9 septembre 2025 à 17h35 (ET) et lors de la H.C. Wainwright 27th Annual Global Investment Conference le 10 septembre 2025 à 9h00 (ET). Les deux présentations seront disponibles en webcast sur le site investisseurs de la société pendant 90 jours après les événements.
TScan Therapeutics (Nasdaq: TCRX), ein Biotech-Unternehmen in der klinischen Phase, das T-Zell-Therapien mit TCR-Engineering zur Krebsbehandlung entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt.
Das Unternehmen wird am Morgan Stanley 23rd Annual Global Healthcare Conference am 9. September 2025 um 17:35 Uhr ET sowie am H.C. Wainwright 27th Annual Global Investment Conference am 10. September 2025 um 09:00 Uhr ET präsentieren. Beide Präsentationen werden im Anschluss 90 Tage lang per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
- Morgan Stanley 23rd Annual Global Healthcare Conference; the fireside chat will be held at the Sheraton New York Times Square on Tuesday, September 9, 2025 at 5:35 p.m. ET
- H.C. Wainwright 27th Annual Global Investment Conference; the presentation will be held at the Lotte New York Palace Hotel on Wednesday, September 10, 2025 at 9:00 a.m. ET
Webcasts of the fireside chat and presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. Archived replays of the webcasts will be available on the Company’s website for 90 days following the events.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Melissa Forst
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
When is TScan Therapeutics (TCRX) presenting at the Morgan Stanley Healthcare Conference 2025?
Where can I watch TScan Therapeutics' (TCRX) investor conference presentations?
What type of company is TScan Therapeutics (TCRX)?
Which investor conferences will TScan Therapeutics (TCRX) attend in September 2025?
